)’s $30 billion Viking Global hedge fund has invested in a new class of cancer drugs being developed by Calithera Biosciences Inc. (NASDAQ:CALA
), it announced on Tuesday evening, via a stake worth 7.8% of its shares.
Halvorsen purchased 1,607,936 shares of the company on Feb. 8, when its price closed at $9 per share, for a total cost of $14.5 million. For the year through the date of Halvorsen’s transaction, the biotech company’s stock price had bounded 177%, but it remains down about 6% since going public in October 2014. Continue Reading »